A Clinical Trial to evaluate the Malbet Product for Malaria.

An Open Label, Phase III Clinical Trial To Assess the Therapeutic Efficacy & Safety Of Malbet Capsules in the treatment Of Malaria

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/08/002913

Enrollment

Registered

2012-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Malaria

Interventions

Intervention1: Malbet: Malbet 340 mg, three capsules a day for 5 days Control Intervention1: Placebo: Placebo

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age above 18 years. 2. Both the sex. 3. Patients suffering with malaria. 4. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients below 18 years of age. 2. Pregnant Women. 3. Patient not willing to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Clinical recovery from the current symptoms of malaria.Timepoint: 5 Days	—

Secondary

Measure	Time frame
To determine the safety profile of Malbet Capsules in malaria sufferers.Timepoint: 5 Days	—

Countries

India

Contacts

Public ContactMr Lanka Srinivas

Sanjeevani Life Sciences

srinivas.lanka@sanjeevaniservices.com9989053518

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026